Article
Multidisciplinary Sciences
Nichole Owen, Irina G. Minko, Samantha A. Moellmer, Sydney K. Cammann, R. Stephen Lloyd, Amanda K. McCullough
Summary: Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents. Specifically, in acute myeloid leukemia (AML), AML cell lines deficient in OGG1 have enhanced sensitivity to cytarabine (Ara-C) treatment. This enhanced cytotoxicity is likely due to the insertion of Ara-C opposite unrepaired 8-oxo-dG in OGG1-deficient AML cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Hematology
Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel
Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tomislav Smoljo, Barbara Tomic, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Antonio Bedalov, Dora Visnjic
Summary: This study demonstrates that bone marrow stroma reduces differentiation of acute myeloid leukemia (AML) induced by low-dose cytarabine (LDAC). These findings provide insights into the limited occurrence of terminal differentiation observed in AML patients and suggest a potential explanation for this observation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Carla S. S. Walti, Anna B. B. Halpern, Hu Xie, Erika S. S. Kiem, E. Lisa Chung, Kelda G. G. Schonhoff, Emily M. M. Huebner, Colleen Delaney, Catherine Liu, Steven A. A. Pergam, Guang-Shing Cheng, Louise E. E. Kimball, Wendy M. M. Leisenring, Michael Boeckh, Roland B. B. Walter, Joshua A. A. Hill
Summary: Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Patients receiving CLAG-M for newly diagnosed or relapsed/refractory AML have higher rates of moderate to severe infections, especially in the case of relapsed/refractory disease. Improved strategies for infection prevention are needed.
Article
Biochemistry & Molecular Biology
Nienke Visser, Harm Jan Lourens, Gerwin Huls, Edwin Bremer, Valerie R. Wiersma
Summary: The study found that the activity of the autophagy pathway did not differ between AraC-Res AML cells and parental AraC-sensitive AML cells, and treatment with autophagy inhibitors did not re-sensitize AraC-Res AML cells to AraC. However, in parental AraC-sensitive AML cells, treatment with AraC activated autophagy and a combination with autophagy inhibitors significantly reduced cell viability. Additionally, the combination of these drugs resulted in the highest level of cell death in patient-derived AML samples, although not additive.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Madeleine A. Ochs, Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Dale L. Bixby, Kristen M. Pettit, Lydia L. Benitez
Summary: There were no significant differences in safety or efficacy outcomes for obese versus non-obese patients who received HIDAC consolidation, suggesting that weight does not impact the dosage of this therapy.
Article
Genetics & Heredity
Jiwon Yun, Hyojin Song, Sung-Min Kim, Soonok Kim, Seok Ryun Kwon, Young Eun Lee, Dajeong Jeong, Jae Hyeon Park, Sunghoon Kwon, Hongseok Yun, Dong Soon Lee
Summary: This study investigated the clinical characteristics and genetic variant profiles in T-MN patients, and compared the findings with previous studies. The results showed that T-MN patients were relatively young and had complex karyotypes. The most common primary diseases were non-Hodgkin lymphoma and breast cancer. These findings are important for the diagnosis and treatment of T-MN patients.
Article
Nanoscience & Nanotechnology
Lejiao Jia, Huatian Yang, Dandan Zheng, Jingjing Ye, Qian Zhou, Genjv Li, Ying Zhou, Xinyu Yang, Jinting Liu, Feng Ye, Yuliang Song, Daoxin Ma, Chunyan Ji
Summary: This study synthesized a mercaptopropionic acid-substituted derivative of Ara-C and used it as a trigger to fabricate a smart cytarabine and venetoclax-coloaded nanoparticle (AV-NP) with redox-responsive drug release, rapid uptake by leukemia cells, and long circulation retention. The AV-NP showed higher antileukemia activity and better safety in the hematologic system compared to free drugs, and significantly improved the therapeutic effect on orthotopic AML mice in vivo.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Hematology
Kittisak Tangchitpianvit, Ekarat Rattarittamrong, Chatree Chai-Adisaksopha, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Adisak Tantiworawit, Lalita Norasetthada
Summary: The study compared the efficacy of intermediate-dose cytarabine (IDAC) and high-dose cytarabine (HiDAC) as consolidation chemotherapy for acute myeloid leukemia (AML), finding no significant difference in one-year relapse-free survival rate and overall survival rate between the two groups. The duration of grade 3-4 thrombocytopenia was significantly shorter in the IDAC group. It is important to weigh the benefits and side effects when choosing between different treatment options.
Article
Medicine, General & Internal
Li Ye, Lingsu Gao, Qiansong Cheng, Feng Guo, Liang He, Tingting Yuan, Ming Zhu, Yuanfang Ma, Min Pan, Xiandeng Chu, Meiqi Ding, Guohui Yu
Summary: The study found that AML patients receiving single-intermediate dose cytarabine after reaching CR showed better relapse-free time and similar toxic effects compared to those receiving standard-dose cytarabine, indicating that ID cytarabine can improve the prognosis of AML patients.
Article
Oncology
Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri
Summary: The original medication instruction sheets (MIS) for monitoring adverse events (AEs) during chemotherapy did not accurately predict the type and time course of AEs in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine (HD-AraC). However, after modifying the MIS based on AE monitoring data, the prediction accuracy significantly improved.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Wenhui Li, Katherine Richter, Jamie Lee, Kevin McCarthy, Timothy Kubal
Summary: The study retrospectively analyzed acute myeloid leukemia patients treated with inpatient/outpatient high-dose cytarabine or intermediate-dose cytarabine consolidation therapy at Moffitt Cancer Center from January 1, 2015, through November 1, 2018. The inpatient/outpatient administration of high-dose cytarabine and intermediate-dose cytarabine is both safe and feasible. Transitioning high-dose cytarabine/intermediate-dose cytarabine administration to the outpatient setting resulted in significant additional revenue compared to inpatient administration.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Oncology
Lydia L. Benitez, Anthony J. Perissinotti, Caitlin R. Rausch, Jeff Klaus, Stephen Michael Clark, Michael Filtz, Kelley Ratermann, Carissa Treptow, Shawn Griffin, Marissa Olson, Mallory Crain, Tapan Kadia, Kristen Pettit, Patrick W. Burke, Dale L. Bixby, Bernard L. Marini
Summary: In newly diagnosed sAML patients, HIDAC-based regimens show comparable efficacy and favorable safety compared to CPX-351, with similar rates of complete response and shorter time to count recovery.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic Moore, Karen P. McKinnon, Alec D. Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan A. Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo
Summary: The study demonstrated that pembrolizumab following high-dose cytarabine in relapsed/refractory AML patients was well-tolerated and feasible, showing promising clinical activity, especially in refractory AML and those receiving treatment as first salvage regimen. Further exploration of pembrolizumab and other immune-checkpoint blockade strategies post cytotoxic chemotherapy is recommended in AML.
BLOOD CANCER DISCOVERY
(2021)
Article
Multidisciplinary Sciences
R. F. Schlenk, D. Weber, J. Krzykalla, T. Kindler, G. Wulf, B. Hertenstein, H. R. Salih, T. Suedhoff, J. Krauter, U. Martens, S. Wessendorf, V. Runde, H. J. Tischler, M. Bentz, E. Koller, M. Heuser, F. Thol, A. Benner, A. Ganser, K. Doehner, H. Doehner
Summary: The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with non-intensive chemotherapy in older unfit patients with newly diagnosed NPM1-mutated acute myeloid leukemia. The study found that adding ATRA to the chemotherapy regimen did not have any beneficial effects and actually led to a worse outcome for older, unfit patients.
SCIENTIFIC REPORTS
(2023)
Article
Medical Laboratory Technology
Alexander Chan, Priyadarshini Kumar, Qi Gao, Jeeyeon Baik, Allison Sigler, Dory Londono, Ying Liu, Maria E. Arcila, Ahmet Dogan, Yanming Zhang, Mikhail Roshal, Wenbin Xiao
Summary: Lineage infidelity, characterized by abnormal immature B lineage output, is rare but detectable in patients with MDS and non-CML MPN. Most cases with abnormal B-lymphoblast populations remain stable or disappear, with only a small percentage progressing to B-ALL. Further investigation is needed to understand the underlying disease biology and its implications for patient management.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Hematology
Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.
Article
Hematology
Misha C. Tran, Yasmin Hasan, Amy Wang, Kamil Yenice, Julien Partouche, Wendy Stock, Richard A. Larson, Satyajit Kosuri, James L. LaBelle, Justin Kline, Peter A. Riedell, Andrew S. Artz, Ralph Weichselbaum, Michael R. Bishop, Bulent Aydogan, Hongtao Liu
Summary: Relapse after allo-SCT is a common issue, and a second SCT can be considered for treatment. The study explored the feasibility of combining IM-TMI with fludarabine and melphalan for conditioning in patients undergoing a second or greater allo-SCT. The results showed that the combination therapy was feasible and achieved favorable outcomes.
Article
Hematology
Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel
Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Wenmin Tang, Yanming Zhang, Keli Yang, Jianjiang Ma, Lian Dong, Chen Wu, Rongxue Lv, Chuanhao Wang, Chuan Luo, Huojun Zhang, Zhenyuan Miao, Yuelin Wu
Summary: Novel 3,11-bispeptide ester derivatives of arenobufagin were designed and synthesized, and their in vitro antiproliferative activity was evaluated. The results showed that the moiety at C3 and C11 hydroxy had a significant impact on cytotoxic activity and selectivity. Compound ZM350 significantly inhibited tumor growth by 58.8% in an A549 nude mice xenograft model at a dose of 10 mg/kg. These findings suggest that the novel 3,11-bispeptide ester derivatives have the potential to be developed as antitumor agents.
CHEMISTRY & BIODIVERSITY
(2023)
Article
Oncology
Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah, Timothy P. Hughes
Summary: Asciminib, a BCR-ABL1 inhibitor that works through the STAMP mechanism, has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase. The ongoing ASC4FIRST trial aims to compare the effectiveness of Asciminib with investigator-selected TKIs in newly diagnosed patients with chronic myeloid leukemia.
Letter
Hematology
Ying Liu, Andriy Derkach, Natasha Lewis, Menglei Zhu, Yanming Zhang, Maria Arcila, Gilles Salles, Ahmet Dogan, Wenbin Xiao
Article
Engineering, Electrical & Electronic
Gaojing Zhang, Ming Su, Yanming Zhang, Anna Wang, Chengkang Pan
Summary: This article presents the design process of a beam-steering partially reflective surface (PRS) made up of C-shaped split-ring resonators (CSRRs). By analyzing the transmission characteristics of CSRRs with variable opening angles and orientations, spatially abrupt phase and magnitude are introduced over the PRS to reshape the wavefronts of linear polarization waves. Four arrangements of 5 x 5 CSRRs are fabricated to validate the design methodology of beam steering based on the designed two distributions and the two control methods. Furthermore, two reconfigurable Fabry-Perot (FP) antennas are proposed based on liquid-metal and mechanically rotating reconfiguration, demonstrating higher aperture efficiency, desirable radiation patterns, and excellent reconfiguration reliability. Moreover, an eight-element phased array combined with a liquid-metal PRS is fabricated and shows improved scanning performance and stable gain fluctuation.
IEEE TRANSACTIONS ON ANTENNAS AND PROPAGATION
(2023)
Article
Multidisciplinary Sciences
Manqing Liu, Shiting Ding, Qintian Pan, Yanming Zhang, Jingru Zhang, Qiong Yang, Tongtong Fang
Summary: The macro policy of the stock market is an important piece of market information aimed at improving market effectiveness. Empirical data is needed to verify whether this goal has been achieved. The utility of this information is closely linked to the effectiveness of the stock market.
Article
Oncology
Naval G. Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N. Tanaka, Terrence J. Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman
Summary: Magrolimab combined with azacitidine showed promising efficacy and tolerability in patients with untreated AML ineligible for intensive chemotherapy, including those with TP53 mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Computer Science, Artificial Intelligence
Yu-Ting Yang, Yan-Ming Zhang, Xiao-Long Yun, Fei Yin, Cheng-Lin Liu
Summary: Online handwriting is widely used in various domains. This paper introduces a method called Dynamic Graph ATtention network (DyGAT) to solve the dynamic stroke classification problem. The core idea is to formalize a document/sketch as a multifeature graph with nodes representing strokes and edges representing their relationships. The proposed method is applicable to different types of online handwritten data and achieves competitive performance in various tasks.
PATTERN RECOGNITION
(2023)
Article
Multidisciplinary Sciences
Shiting Ding, Qintian Pan, Yanming Zhang, Jingru Zhang, Qiong Yang, Jingdong Luan
Summary: The Chinese economy has undergone a long-term transition reform, but there is still financial repression in the financial sector. China's actual interest rate has remained higher than the CPI for most years since 1999, which is inconsistent with financial repression. This is due to the calculation methods of China's CPI, which does not fully consider the rise in housing prices.
Meeting Abstract
Oncology
Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla Heavican-Foral, Huiyun Liu, Geoffrey Nelson, Lu Yang, Renee Chen, Katherine Donovan, Marcus Jones, Mikhail Roshal, Yanming Zhang, Ran Xu, Ajit Nirmal, Salvia Jain, Catharine Leahy, Kristen Jones, Kristen Stevenson, Natasha Galasso, Nivetha Ganesan, Tiffany Chang, Wen-Chao Wu, Abner Louissaint, Lydie Debaize, Hojong Yoon, Paola Dal Cin, Wing Chan Chan, Shannan Ho Ho Sui Sui, Samuel Ng, Andrew Feldman, Steven M. Horwitz, Mathew Meyerson, Karen Adelman, Eric Fischer, Chun-Wei Chen, David Weinstock, Myles Brown
Meeting Abstract
Medicine, Research & Experimental
Dianne Torrence, Josephine Dermawan, Yanming Zhang, Chad Vanderbilt, Kerry Mullaney, Achim Jungbluth, Purvil Sukhadia, Narasimhan Agaram, Meera Hameed
LABORATORY INVESTIGATION
(2023)
Article
Hematology
Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, GaryJ. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Yoshinobu Maeda, Naoko Hosono, Masahiro Onozawa, Takayasu Kato, Hee-Je Kim, Nahla Hasabou, Rishita Nuthethi, Ramon Tiu, Mark J. Levis
Summary: The ADMIRAL trial investigated the efficacy of using the FLT3 inhibitor gilteritinib as maintenance therapy after hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory FLT3-mutated AML. The results showed that gilteritinib maintenance therapy improved survival rates and was well-tolerated in patients post-HSCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
